Having trouble accessing articles? Reset your cache.

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Biotechs, academics turn to partnerships to overcome manufacturing barriers to gene and cell therapies

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply.

At least seven manufacturing deals and site launches in January underscore different techniques companies and academics are employing in order to break through the capacity constraints for gene and cell therapies.

Manufacturing teamwork

On Thursday, Deerfield Management and The Discovery Labs launched a contract development and manufacturing organization that will provide preclinical through commercial manufacturing of cell and gene therapies, as well as component raw materials.

According to the partners, the CDMO,

Read the full 974 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE